• December 1, 2022

  EISAI TO PRESENT PRECLINICAL AND CLINICAL RESEARCH ON ERIBULIN AT THE 2022 SAN ANTONIO BREAST CANCER SYMPOSIUM

• November 30, 2022

  EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER’S DISEASE AT CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE

• November 30, 2022

  ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER’S DISEASE IN THE NEW ENGLAND JOURNAL OF MEDICINE

• November 29, 2022

  (REVISION) ARTICLE REGARDING SAFETY INFORMATION OF LECANEMAB REPORTED BY SCIENCEINSIDER

• November 29, 2022

  EISAI ANNOUNCES APPROVAL OF PARTIAL CHANGE TO LABEL FOR DOSAGE AND ADMINISTRATION OF ARICEPT® FOR TREATMENT OF DEMENTIA WITH LEWY BODIES

View All

• November 30, 2022

  Wednesday, November 30, 2022 09:50 a.m.- (JST)
  Full Findings of Lecanemab Confirmatory Phase 3 Clinical Trial (Clarity AD) at Clinical Trials on Alzheimer's Disease (CTAD) 2022 [Material]

• November 15, 2022

  Sustainability "Request to Position “Global Health” as a Major Pillar of the Next Development Cooperation CharterーA Letter of Request was Delivered to Mr. Yoshimasa Hayashi, Minister of Foreign Affairs"

• November 8, 2022

  IR “Second Quarter Financial Results Briefing for the Fiscal Year Ending March 31, 2023 [Material, Webcast]”

• November 8, 2022

  About Eisai “Corporate Governance Report Notice”

• November 7, 2022

  IR “Second Quarter Financial Report for the Fiscal Year Ending March 31, 2023”

View All

• July 15, 2022

  Notification Regarding U.S. Research and Development Subsidiary

• April 1, 2022

  Humanitarian Support to Ukraine

• November 24, 2021

  Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimer’s Disease

• September 22, 2021

  EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT SIXTH ANNUAL WELFARE INDEX PMI* IN ITALY

• April 19, 2021

  Eisai formulates the action plan “Diversity & Inclusion 2021”

View All